Max India Limited (MAXIND) has reported its financial performance for Q2FY’27, showcasing a significant revenue growth of 89% year-on-year (YoY) and a notable reduction in EBITDA loss by 55% YoY. The company’s strong performance is driven by its key segments, particularly in Residences for Seniors and Care Homes & AGEasy.

Residencies for Seniors

The Residences for Seniors segment has seen a remarkable revenue increase of 156% YoY and 35% quarter-on-quarter (QoQ). Notably, the Gurugram E360 project has achieved 100% unit sales within July 2025, and Noida Phase I handovers are underway. Sales collections for Q2FY’27 reached approximately Rs 212 crore, with E361 units selling at a velocity of 31 per month.

Care Homes & AGEasy

The Care Homes & Services revenue grew by 40% YoY and 6% QoQ, with a significant increase in occupied bed days and average revenue per occupied bed (ARPOB). AGEasy, focusing on senior-focused innovative products, reported a revenue of Rs 35 crore, marking a 1.7x YoY growth. The company has also received 8 NABH accreditations for its centres, reinforcing its position as a leader in the senior living sector.

Financial Performance

The consolidated EBITDA loss has been reduced by 55% YoY and 54% QoQ, indicating the emerging path to profitability. With a liquidity position of Rs 395 crore, Max India Limited is well-positioned to navigate future challenges and capitalize on growth opportunities.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Max India Limited

Max India Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Max moves sideways over three months, with neither buyers nor sellers taking control. Industry-leading margins of 55.4% reflect exceptional pricing power and operational efficiency. 5 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock gains 13.3% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Price climbs recently despite -1.8% revenue growth and a PEG of 99.00. Consequently, either institutions position ahead of improvement or the move fades when earnings disappoint. Treat this as a trading signal, not an investment thesis. Check Fundamentals of Max India Limited.

Neuland Laboratories Limited (NSE: NEULANDLAB) announced its unaudited Standalone Financial Results for the quarter and half year ended September 30, 2026, as approved by its Board of Directors. The company reported a standalone revenue of ₹457.2 Cr for Q2 FY27, a 11.4% decrease year-on-year. Despite the dip, the company’s EBITDA stood at ₹104.6 Cr, with an EBITDA margin of 22.9%.

Financial Performance

The Profit After Tax (PAT) for the quarter was ₹51.1 Cr, down from ₹96.5 Cr in Q2 FY26, with a PAT margin at 11.2%. Diluted Earnings Per Share (EPS) for the quarter was ₹39.9, compared to ₹75.2 in Q2 FY26. The company’s working capital efficiency improved, with working capital days reducing to 104 days in H1 FY27 from 155 days in H1 FY26.

Strategic Initiatives

Neuland Laboratories has inaugurated a new peptide manufacturing facility, which is supported by a growing pipeline of upcoming projects. The company also acquired approximately 134 acres of land in Kakinada, AP, providing a strategic base to support its long-term capacity and growth requirements. Additionally, two DMFs were filed in Q2 FY27 for Fezolinetant and Ivacaftor.

Mr. Saharsh Davuluri, Chief Executive Officer and Managing Director, commented on the performance: “While we have experienced a dip in performance this quarter, H1 FY27 was largely in line with plan and our growth expectations remain intact for FY27 and the following year. Commercial CMS molecules continue to drive near-term growth, while strong RFP activity along with progress on traction with Big Pharma support customer diversification and the longer-term pipeline. The investments in peptides, R&D and land acquisition strengthen our capabilities while enabling us to expand with agility.”

Neuland Laboratories Limited will host a one-hour earnings call on Tuesday, November 3, 2026, at 17:30 hrs. IST, during which management will discuss the Company’s performance and respond to questions from participants.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Neuland Laboratories Limited

Neuland Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Neuland posts a 6.7% three-month gain, but softens in the last few weeks. Premium net margins of 21.0% demonstrate strong cost discipline and a wide competitive moat. The business compounds revenue at 18.5% and profits at 30.6% CAGR. That is strong double-digit growth on both counts. RSI stands at 26, well into oversold territory. Yet sellers still dominated on 21 of recent sessions versus 9 for buyers, so the pressure has not fully lifted. The business grows revenue at 18.5% and profits at 30.6%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 1.66 premium is usually justified. Check Fundamentals of Neuland Laboratories Limited.

Kopran Limited (NSE: KOPRAN) has released its quarterly investor presentation for Q2 FY 2026-27, showcasing significant financial and operational highlights. The company, a global pharmaceutical powerhouse, reported robust revenue growth and operational performance across its API and Formulation segments.

Financial Highlights

The company’s revenue from operations for Q2 FY 2026-27 stood at Rs. 21,126 lakhs, marking a substantial increase from Rs. 15,399 lakhs in the same period last year. The EBITDA for the quarter was Rs. 1,822 lakhs, reflecting a healthy margin of 8.62%. Despite a forex loss of Rs. 219 lakhs, the net profit for the quarter was Rs. 439 lakhs, indicating a strong financial performance.

Operational Performance

Kopran Limited’s API segment continued to drive growth, with the company’s Atenolol and Carbapenem products leading the charge. The Formulations segment also performed well, with significant contributions from Anti-Diabetic and Anti-Hypertensive products. The company’s state-of-the-art manufacturing facilities in Maharashtra and Gujarat ensured high compliance with global regulatory standards.

Looking Ahead

Kopran Limited remains committed to driving sustainable growth through strategic imperatives such as capacity expansion, regulatory compliance, and cost optimization. The company’s focus on R&D and capacity enhancement positions it well for future growth and sustainability in the pharmaceutical industry.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Kopran Limited

Kopran Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Kopran gains 33.2% over three months and trades near its 52-week highs. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 1 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. Buyers show up with 5.0x the volume of sellers. Moreover, they dominated on 18 of recent sessions versus 12 for sellers — a healthy accumulation pattern. The stock rises 33.2% in three months. Yet revenue grows at only 7.2% and the PEG stands at 99.00. Either the market prices in a turnaround that has not shown up yet, or this is momentum without substance. Check the next two earnings prints before drawing conclusions. Check Fundamentals of Kopran Limited.